Companies Catalyst Pharmaceuticals
Catalyst Pharmaceuticals (CPRX): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Catalyst Pharmaceuticals’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers13th pct.Of 16 peer CEOs
CEO pay, last three years
- $7,774,160FY2024
CEO total pay was $7,774,160 in fiscal 2024; the brief holds no earlier figure for this CEO.
FY2024: salary $750,000 · bonus $590,625 · stock awards $1,267,601 · option awards $5,070,830
Executives and directors
Preethi Sundaram · Chief Strategy OfficerJeffrey Del Carmen · CCORichard Daly · CEOMichael Kalb · CFOSteven Miller · COOCharles B. O'Keeffe · DirectorDavid S. Tierney · Independent DirectorDonald A. Denkhaus · Independent DirectorMolly Harper · Independent DirectorPatrick J. McEnany · Chair of the BoardTamar Thompson · Independent Director
Frequently asked questions
Who was the highest-paid executive at Catalyst Pharmaceuticals in fiscal 2024?
As disclosed, Richard Daly (President and CEO) was the highest-paid executive at Catalyst Pharmaceuticals in fiscal 2024, with total compensation of $7,774,160.
How does Catalyst Pharmaceuticals's chief executive pay compare to its disclosed peer group?
As disclosed, Richard Daly's total compensation ranked at the 13th percentile of Catalyst Pharmaceuticals's disclosed peer group.
What is Catalyst Pharmaceuticals's CEO-to-median employee pay ratio?
As disclosed, Catalyst Pharmaceuticals's CEO-to-median employee pay ratio was 21:1.
How did shareholders vote on Catalyst Pharmaceuticals's executive compensation?
As disclosed, 92.73% of shareholders supported Catalyst Pharmaceuticals's executive compensation in the latest say-on-pay vote.
How much does Catalyst Pharmaceuticals spend in total on board compensation for fiscal 2024?
As disclosed, Catalyst Pharmaceuticals reported total board compensation of $2,840,854 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Richard Daly | $750,000 | $590,625 | $1,267,601 | $5,070,830 | $0 | $0 | $95,104 | $7,774,160 |
| President and CEO | ||||||||
| Michael Kalb | 525,000 | 350,625 | 1,036,803 | 4,147,345 | 0 | 0 | 121,163 | 6,180,936 |
| EVP and CFO | ||||||||
| Steven Miller | 560,000 | 352,800 | 523,797 | 2,095,377 | 0 | 0 | 13,800 | 3,545,774 |
| COO and CSO | ||||||||
| Jeffrey Del Carmen | 525,000 | 275,625 | 355,006 | 1,420,124 | 0 | 0 | 62,372 | 2,638,127 |
| CCO | ||||||||
| Preethi Sundaram | 485,000 | 254,625 | 355,006 | 1,420,124 | 0 | 0 | 13,800 | 2,528,555 |
| Chief Strategy Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Richard Daly | $7,774,160 | — | — | — |
| Michael Kalb | 6,180,936 | — | — | — |
| Steven Miller | 3,545,774 | 3,404,698 | 3,474,783 | ↑ +141,076 |
| Jeffrey Del Carmen | 2,638,127 | 2,506,066 | 2,386,432 | ↑ +132,061 |
| Preethi Sundaram | 2,528,555 | 2,145,798 | 2,138,461 | ↑ +382,757 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The compensation program is designed to provide a competitive level of base salary reflecting position responsibilities and strategic importance, a cash-based short-term incentive to recognize the achievement of annual goals, and long-term equity incentives to align management with long-term stockholder value creation and retention.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Mercer LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jeffrey Del Carmen | OPTION | 2024-11-21 | — | — | 137,553 | — | $1,420,124 |
| Preethi Sundaram | OPTION | 2024-11-21 | — | — | 137,553 | — | 1,420,124 |
| Richard Daly | OPTION | 2024-11-21 | — | — | 491,160 | — | 5,070,830 |
| Steven Miller | OPTION | 2024-11-21 | — | — | 202,958 | — | 2,095,377 |
| Michael Kalb | OPTION | 2024-01-01 | — | — | 257,214 | — | 2,399,996 |
| Michael Kalb | OPTION | 2024-11-21 | — | — | 169,248 | — | 1,747,349 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jeffrey Del Carmen | $0 | $0 | $1,420,124 | 0.0% |
| Preethi Sundaram | 0 | 0 | 1,420,124 | 0.0% |
| Richard Daly | 0 | 0 | 5,070,830 | 0.0% |
| Steven Miller | 0 | 0 | 2,095,377 | 0.0% |
| Michael Kalb | 0 | 0 | 4,147,345 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Richard Daly | Option | 5,000 | 18.59 | — |
| Preethi Sundaram | Option | 22,667 | 18.59 | — |
| Jeffrey Del Carmen | Option | 29,334 | 18.59 | — |
| Jeffrey Del Carmen | Option | 30,000 | 4.7 | — |
| Steven Miller | Option | 48,667 | 18.59 | — |
| Preethi Sundaram | Option | 75,000 | 5.49 | — |
| Preethi Sundaram | Option | 95,462 | 14.15 | — |
| Jeffrey Del Carmen | Option | 111,946 | 14.15 | — |
| Jeffrey Del Carmen | Option | 137,553 | 21.12 | — |
| Preethi Sundaram | Option | 137,553 | 21.12 | — |
| Steven Miller | Option | 165,336 | 14.15 | — |
| Michael Kalb | Option | 169,248 | 21.12 | — |
| Steven Miller | Option | 202,958 | 21.12 | — |
| Michael Kalb | Option | 257,214 | 16.81 | — |
| Richard Daly | Option | 491,160 | 21.12 | — |
| Richard Daly | Option | 1,365,319 | 13.3 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Patrick J. McEnanyNot independent · Board Chair | $282,211 | $562,548 | — | — | — | $844,759 |
| Molly HarperIndependent · Lead Independent Director · Compensation · Corporate Governance · Nominating | 139,125 | 300,019 | — | — | — | 439,144 |
| Charles B. O'KeeffeNot standing for re-election | 108,625 | 300,019 | — | — | — | 408,644 |
| Donald A. DenkhausIndependent · Audit (Chair) · Corporate Governance · Nominating | 86,250 | 300,019 | — | — | — | 386,269 |
| Tamar ThompsonIndependent · Corporate Governance and Nominating (Chair) · Audit | 81,000 | 300,019 | — | — | — | 381,019 |
| David S. TierneyIndependent · Compensation (Chair) · Corporate Governance and Nominating | 81,000 | 300,019 | — | — | — | 381,019 |
| Richard J. DalyEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | $300,019 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 21,000 / 15,750 / 10,500 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $778,211 |
| Equity awards (grant-date value) | $2,062,643 |
| All other compensation | $0 |
| Total cost of the board | $2,840,854 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Catalyst Pharmaceuticals as a peer
Companies that benchmark against CPRX
16 companies name CPRX as a compensation peer
The list of companies that name CPRX as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
FOLD Amicus Therapeutics, Inc.AMPH Amphastar Pharmaceuticals, Inc.DVAX Dynavax Technologies CorporationHALO Halozyme Therapeutics, Inc.IONS Ionis Pharmaceuticals, Inc.IRWD Ironwood Pharmaceuticals, Inc.PCRX Pacira BioSciences, Inc.PTCT PTC Therapeutics, Inc.INSM Insmed IncorporatedCOLL Collegium Pharmaceutical, Inc.RARE Ultragenyx Pharmaceutical, Inc.ANIP Ani Pharmaceuticals, Inc.ACAD Acadia Pharmaceuticals Inc.CORT Corcept Therapeutics Incorporated Supernus Pharmaceutials, Inc.HRMY Harmony Biosciences Holdings, Inc.
Peer reciprocity
The companies Catalyst Pharmaceuticals names as compensation peers that name it back in their own disclosed peer groups.
Amicus Therapeutics, Inc. (FOLD)242Collegium Pharmaceutical, Inc. (COLL)243Ani Pharmaceuticals, Inc. (ANIP)244Acadia Pharmaceuticals Inc. (ACAD)245
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | PTC Therapeutics, Inc. | 2025 | Matthew Klein | $958,500 | $16,593,800 | $4,399,760 | $1,294,000 | $23,266,326 |
| 2 | Halozyme Therapeutics, Inc. | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 3 | Corcept Therapeutics Incorporated | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 4 | Insmed Incorporated | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 5 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 6 | Pacira BioSciences, Inc. | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 7 | Ultragenyx Pharmaceutical, Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 8 | Ani Pharmaceuticals, Inc. | 2025 | Nikhil Lalwani | 837,409 | 7,848,711 | 0 | 1,572,500 | 10,278,620 |
| 9 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 10 | Amphastar Pharmaceuticals, Inc. | 2025 | Jack Yongfeng Zhang | 950,911 | 3,301,981 | 3,302,024 | 361,000 | 8,309,350 |
| 11 | Acadia Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 12 | Dynavax Technologies Corporation | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 13 | Harmony Biosciences Holdings, Inc. | 2025 | Jeffrey Dayno | 743,600 | 1,976,520 | 4,599,000 | 558,000 | 7,899,535 |
| 14 | Catalyst Pharmaceuticals | 2024 | Richard Daly | 750,000 | 1,267,601 | 5,070,830 | 0 | 7,774,160 |
| 15 | Ironwood Pharmaceuticals, Inc. | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
| 16 | Collegium Pharmaceutical, Inc. | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Catalyst Pharmaceuticals | not disclosed | not disclosed | not disclosed | Mercer LLC |
| Acadia Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Amphastar Pharmaceuticals, Inc. | not disclosed | Options 50 · RSU 50 | not disclosed | Willis Towers Watson (WTW) |
| Ani Pharmaceuticals, Inc. | 185% | RSU 75 · PSU 25 | Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences Index | Pearl Meyer & Partners, LLC |
| Collegium Pharmaceutical, Inc. | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Corcept Therapeutics Incorporated | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Dynavax Technologies Corporation | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Halozyme Therapeutics, Inc. | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Harmony Biosciences Holdings, Inc. | 100% | not disclosed | not disclosed | Pay Governance |
| Insmed Incorporated | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Ionis Pharmaceuticals, Inc. | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Ironwood Pharmaceuticals, Inc. | 100% | RSU 50 · PSU 50 | not disclosed | Alpine Rewards LLC |
| Pacira BioSciences, Inc. | 90% | RSU 80 · PSU 20 | No | Aon |
| PTC Therapeutics, Inc. | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Ultragenyx Pharmaceutical, Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-05-20 | 82,734,939 | 6,484,020 | 203,472 | 92.73% | Passed |
| 2024 | 2024-05-21 | 84,194,484 | 5,468,681 | 181,674 | 93.9% | Passed |
| 2023 | 2023-08-22 | 72,610,991 | 2,909,780 | 437,050 | 96.15% | Passed |
| 2022 | 2022-09-19 | 66,515,582 | 2,124,782 | 111,352 | 96.9% | Passed |
| 2021 | 2021-12-03 | 59,092,977 | 3,432,904 | 246,626 | 94.51% | Passed |
| 2020 | 2020-08-20 | 56,150,772 | 1,880,451 | 412,646 | 96.08% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-05-20 | 92.73%a |
| 2024 | 2024-05-21 | 93.9%b |
| 2023 | 2023-08-22 | 96.15%c |
a. Approved under the standard stated in the filing — “Abstentions will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal.”.
b. Approved under the standard stated in the filing — “Abstentions will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal.”.
c. Approved under the standard stated in the filing — “Abstentions will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 21 : 1 |
|---|---|
| CEO total compensation | $7,774,160 |
| Median employee compensation | $370,800 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Patrick J. McEnany | Director | 2025-11-21 | A | 1,775 | — | — | Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2025-11-21 | D | 2,485 | — | — | Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2025-11-21 | A | 6,894 | — | — | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-11-21 | A | 5,603 | — | — | Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-11-21 | D | 5,161 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-11-21 | D | 2,030 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2025-11-21 | D | 7,872 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-11-26 | A | 10,983 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-11-26 | D | 10,983 | 23 | 256,244 | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-11-26 | A | 10,983 | 4 | 46,238 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-01 | D | 45,000 | 0 | 0 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-01 | D | 45,000 | 0 | 0 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-01 | D | 45,000 | 0 | 0 | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-08 | D | 1,669 | — | — | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-08 | A | 6,855 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-12-08 | — | 5,652 | — | — | 4 insiders, 4 accrual rows | ||
| Molly Harper | Director | 2025-12-08 | A | 1,413 | — | — | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-08 | A | 3,534 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-08 | D | 2,492 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-08 | A | 8,039 | — | — | Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2025-12-08 | A | 11,873 | — | — | Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-08 | D | 7,067 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-08 | D | 6,855 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-08 | D | 8,039 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-08 | A | 7,067 | — | — | Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2025-12-08 | D | 11,873 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2025-12-08 | A | 1,413 | — | — | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-08 | D | 3,534 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2025-12-08 | A | 1,413 | — | — | Common | Form 4 ↗ |
| David S. Tierney | Director | 2025-12-08 | A | 1,413 | — | — | Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-08 | D | 2,780 | — | — | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | D | 6,746 | 23 | 155,563 | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | D | 15,527 | 23 | 360,195 | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | A | 20,000 | 6 | 115,600 | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | D | 4,473 | 24 | 106,162 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-12-29 | — | 5,336 | — | — | 4 insiders, 4 accrual rows | ||
| Patrick J. McEnany | Director | 2025-12-29 | D | 26,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-29 | D | 6,786 | — | — | Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2025-12-29 | D | 14,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2025-12-29 | A | 14,000 | — | — | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-29 | A | 6,667 | — | — | Common | Form 4 ↗ |
| David S. Tierney | Director | 2025-12-29 | A | 1,334 | — | — | Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-29 | D | 2,623 | — | — | Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-29 | D | 6,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-29 | D | 6,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-29 | A | 6,667 | — | — | Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2025-12-29 | A | 1,334 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-29 | D | 8,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-29 | D | 3,839 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2025-12-29 | D | 524 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2025-12-29 | A | 1,334 | — | — | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-29 | A | 26,334 | — | — | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-29 | A | 1,334 | — | — | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-29 | D | 2,369 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-29 | A | 8,667 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-01-05 | D | 42,105 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2026-01-05 | A | 7,139 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-01-05 | D | 10,577 | — | — | Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2026-01-05 | D | 7,139 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-01-05 | A | 42,105 | — | — | Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2026-01-05 | D | 2,080 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-02-17 | — | 687 | — | — | 1 insider, 1 accrual row | ||
| Gregg Russo | Chief HR Officer | 2026-02-17 | D | 211 | — | — | Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-02-17 | A | 687 | — | — | Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-06-03 | D | 743 | — | — | Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-06-03 | A | 3,052 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-15 | — | 13,232 | — | — | 4 insiders, 8 accrual rows | ||
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 6,957 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 39,701 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 131,536 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 13,665 | 32 | 430,448 | Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 29,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 3,694 | 32 | 116,361 | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 40,013 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 491,160 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 32,257 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 11,206 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 143,193 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 11,206 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 8,039 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 167,918 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 150,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 33,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 34,921 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 740,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 6,197 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 23,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 29,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 11,873 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 158,454 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 275,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 180,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 1,093,803 | 32 | 34,454,795 | Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 23,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Curran | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Curran | Director | 2026-07-15 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 7,067 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 147,621 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 135,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 6,855 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 106,873 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 43,591 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 270,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 476 | 32 | 14,994 | Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 3,773 | 32 | 118,850 | Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 33,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 169,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 3,534 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 23,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 2,309 | 32 | 72,734 | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 1,365,319 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 106,873 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 67,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 54,804 | 32 | 1,726,326 | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 137,553 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 135,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 14,337 | 32 | 451,616 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 10,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 16,534 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 202,958 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 29,776 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 98,652 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 126,704 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 257,214 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 13,788 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 98,652 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 124,447 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 115,283 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 381,948 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 33,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 68,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 225,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 32,257 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 88,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 23,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 29,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 498,773 | 32 | 15,711,350 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 73,810 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 272,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 400,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 4,171,559 | 32 | 131,404,109 | Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 2,752 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 20,531 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 20,349 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 146,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 185,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 29,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 383,314 | 32 | 12,074,391 | Common | Form 4 ↗ |
| Daniel J. Curran | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 69,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 132,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 242,501 | 32 | 7,638,782 | Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 21,416 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 29,776 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 271,266 | 32 | 8,544,879 | Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 3,552 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 47,826 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 248,004 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 10,322 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 12,209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 126,316 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 137,553 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 200 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Patrick J. McEnany | Director | 2025-11-21 | A | 1,775 | — | — | Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2025-11-21 | D | 2,485 | — | — | Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2025-11-21 | A | 6,894 | — | — | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-11-21 | A | 5,603 | — | — | Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-11-21 | D | 5,161 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-11-21 | D | 2,030 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2025-11-21 | D | 7,872 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-11-26 | A | 10,983 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-11-26 | D | 10,983 | 23 | 256,244 | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-11-26 | A | 10,983 | 4 | 46,238 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-01 | D | 45,000 | 0 | 0 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-01 | D | 45,000 | 0 | 0 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-01 | D | 45,000 | 0 | 0 | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-08 | D | 1,669 | — | — | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-08 | A | 6,855 | — | — | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-08 | D | 1,413 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-08 | A | 1,413 | — | — | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-08 | A | 3,534 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-08 | D | 2,492 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-08 | A | 8,039 | — | — | Common | Form 4 ↗ |
| Tamar Thompson | Director | 2025-12-08 | D | 1,413 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2025-12-08 | A | 11,873 | — | — | Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-08 | D | 7,067 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-08 | D | 6,855 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-08 | D | 8,039 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-08 | A | 7,067 | — | — | Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2025-12-08 | D | 11,873 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2025-12-08 | A | 1,413 | — | — | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-08 | D | 3,534 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2025-12-08 | A | 1,413 | — | — | Common | Form 4 ↗ |
| David S. Tierney | Director | 2025-12-08 | D | 1,413 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2025-12-08 | A | 1,413 | — | — | Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2025-12-08 | D | 1,413 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-08 | D | 2,780 | — | — | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | D | 6,746 | 23 | 155,563 | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | D | 15,527 | 23 | 360,195 | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | A | 20,000 | 6 | 115,600 | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | D | 4,473 | 24 | 106,162 | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2025-12-29 | D | 1,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-29 | D | 26,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-29 | D | 6,786 | — | — | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-29 | D | 1,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2025-12-29 | D | 14,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2025-12-29 | A | 14,000 | — | — | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-29 | A | 6,667 | — | — | Common | Form 4 ↗ |
| David S. Tierney | Director | 2025-12-29 | A | 1,334 | — | — | Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-29 | D | 2,623 | — | — | Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2025-12-29 | D | 1,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-29 | D | 6,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-29 | D | 6,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-29 | A | 6,667 | — | — | Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2025-12-29 | A | 1,334 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-29 | D | 8,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-29 | D | 3,839 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2025-12-29 | D | 524 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2025-12-29 | A | 1,334 | — | — | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-29 | A | 26,334 | — | — | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-29 | A | 1,334 | — | — | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-29 | D | 2,369 | — | — | Common | Form 4 ↗ |
| David S. Tierney | Director | 2025-12-29 | D | 1,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-29 | A | 8,667 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-01-05 | D | 42,105 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2026-01-05 | A | 7,139 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-01-05 | D | 10,577 | — | — | Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2026-01-05 | D | 7,139 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-01-05 | A | 42,105 | — | — | Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2026-01-05 | D | 2,080 | — | — | Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-02-17 | D | 687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-02-17 | D | 211 | — | — | Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-02-17 | A | 687 | — | — | Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-06-03 | D | 743 | — | — | Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-06-03 | A | 3,052 | — | — | Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 1,894 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 6,957 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 39,701 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 131,536 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 13,665 | 32 | 430,448 | Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 1,414 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 29,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 3,694 | 32 | 116,361 | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 40,013 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 491,160 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 32,257 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 11,206 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 143,193 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 11,206 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 8,039 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 167,918 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 150,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 1,414 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 33,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 34,921 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 740,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 6,197 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 1,894 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 23,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 29,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 11,873 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 158,454 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 275,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 180,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 1,093,803 | 32 | 34,454,795 | Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 23,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Curran | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Curran | Director | 2026-07-15 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 7,067 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 147,621 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 135,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 6,855 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 106,873 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 43,591 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 270,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 476 | 32 | 14,994 | Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 3,773 | 32 | 118,850 | Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 1,414 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 33,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 169,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 3,534 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 23,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 2,309 | 32 | 72,734 | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 1,365,319 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 106,873 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 67,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 54,804 | 32 | 1,726,326 | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 137,553 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 135,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 14,337 | 32 | 451,616 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 10,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 16,534 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 202,958 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 29,776 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 98,652 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 126,704 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 257,214 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 13,788 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 1,894 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 98,652 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 124,447 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 115,283 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 381,948 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 33,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 68,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 225,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 32,257 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 88,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 23,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 29,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 498,773 | 32 | 15,711,350 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 73,810 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 272,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 400,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 4,171,559 | 32 | 131,404,109 | Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 2,752 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 20,531 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 20,349 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 1,414 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 146,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 185,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 29,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 383,314 | 32 | 12,074,391 | Common | Form 4 ↗ |
| Daniel J. Curran | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 69,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 132,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 242,501 | 32 | 7,638,782 | Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 21,416 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 29,776 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 271,266 | 32 | 8,544,879 | Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 3,552 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 47,826 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 248,004 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 1,894 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 10,322 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 12,209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 126,316 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 137,553 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Sources (245 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Richard Daly. DEF 14A, filed 2025-04-11. Section “Executive Compensation” · page 31. As printed: 7,774,160. View filing ↗
- Section 01, Michael Kalb. DEF 14A, filed 2025-04-11. Section “Executive Compensation”. As printed: 6,180,936. View filing ↗
- Section 01, Steven Miller. DEF 14A, filed 2025-04-11. Section “Executive Compensation”. As printed: 3,545,774. View filing ↗
- Section 01, Jeffrey Del Carmen. DEF 14A, filed 2025-04-11. Section “Executive Compensation”. As printed: 2,638,127. View filing ↗
- Section 01, Preethi Sundaram. DEF 14A, filed 2025-04-11. Section “Executive Compensation”. As printed: 2,528,555. View filing ↗
- Section 03, Jeffrey Del Carmen OPTION. DEF 14A, filed 2025-04-11. Section “Grants of Plan-Based Awards for 2024” · grants of plan-based awards table. View filing ↗
- Section 03, Preethi Sundaram OPTION. DEF 14A, filed 2025-04-11. Section “Grants of Plan-Based Awards for 2024” · grants of plan-based awards table. View filing ↗
- Section 03, Richard Daly OPTION. DEF 14A, filed 2025-04-11. Section “Grants of Plan-Based Awards for 2024” · grants of plan-based awards table. View filing ↗
- Section 03, Steven Miller OPTION. DEF 14A, filed 2025-04-11. Section “Grants of Plan-Based Awards for 2024” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Kalb OPTION. DEF 14A, filed 2025-04-11. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Kalb OPTION. DEF 14A, filed 2025-04-11. Section “Grants of Plan-Based Awards for 2024” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2025-04-11. Section “CEO Pay Ratio”. As printed: 21 : 1. View filing ↗
- Section 08, Patrick J. McEnany. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 844,759. View filing ↗
- Section 08, Molly Harper. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 439,144. View filing ↗
- Section 08, Charles B. O'Keeffe. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 408,644. View filing ↗
- Section 08, Donald A. Denkhaus. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 386,269. View filing ↗
- Section 08, Tamar Thompson. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 381,019. View filing ↗
- Section 08, David S. Tierney. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 381,019. View filing ↗
- Section 08, Richard J. Daly. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Patrick J. McEnany 2025-11-21. Form 4, filed 2025-11-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kalb 2025-11-21. Form 4, filed 2025-11-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kalb 2025-11-21. Form 4, filed 2025-11-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2025-11-21. Form 4, filed 2025-11-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2025-11-21. Form 4, filed 2025-11-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2025-11-21. Form 4, filed 2025-11-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2025-11-21. Form 4, filed 2025-11-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2025-11-26. Form 4, filed 2025-11-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2025-11-26. Form 4, filed 2025-11-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2025-11-26. Form 4, filed 2025-11-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2025-12-01. Form 4, filed 2025-12-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2025-12-01. Form 4, filed 2025-12-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2025-12-01. Form 4, filed 2025-12-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tamar Thompson 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Miller 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Miller 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald A. Denkhaus 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tamar Thompson 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Tierney 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Tierney 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald A. Denkhaus 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2025-12-08. Form 4, filed 2025-12-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2025-12-12. Form 4, filed 2025-12-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2025-12-12. Form 4, filed 2025-12-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2025-12-12. Form 4, filed 2025-12-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2025-12-12. Form 4, filed 2025-12-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2025-12-12. Form 4, filed 2025-12-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Miller 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Miller 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Tierney 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald A. Denkhaus 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald A. Denkhaus 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Tierney 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2025-12-29. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2026-01-05. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kalb 2026-01-05. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2026-01-05. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kalb 2026-01-05. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2026-01-05. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kalb 2026-01-05. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg Russo 2026-02-17. Form 4, filed 2026-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg Russo 2026-02-17. Form 4, filed 2026-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg Russo 2026-02-17. Form 4, filed 2026-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William T. Andrews 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William T. Andrews 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald A. Denkhaus 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg Russo 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kalb 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kalb 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kalb 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald A. Denkhaus 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald A. Denkhaus 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg Russo 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tamar Thompson 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tamar Thompson 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tamar Thompson 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Miller 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Miller 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Miller 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Miller 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Miller 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Tierney 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Tierney 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel J. Curran 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel J. Curran 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg Russo 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tamar Thompson 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Tierney 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Tierney 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Tierney 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kalb 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William T. Andrews 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tamar Thompson 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Miller 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Miller 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Tierney 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Tierney 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kalb 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kalb 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Molly Harper 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William T. Andrews 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William T. Andrews 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Del Carmen 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald A. Denkhaus 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald A. Denkhaus 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald A. Denkhaus 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald A. Denkhaus 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald A. Denkhaus 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald A. Denkhaus 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald A. Denkhaus 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg Russo 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg Russo 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg Russo 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregg Russo 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tamar Thompson 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tamar Thompson 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tamar Thompson 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Miller 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Miller 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Tierney 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Tierney 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Tierney 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel J. Curran 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kalb 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William T. Andrews 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald A. Denkhaus 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick J. McEnany 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Miller 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Miller 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Tierney 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Elsbernd 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William T. Andrews 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard J. Daly 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Preethi Sundaram 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-23. Item 5.07 · say-on-pay result. As reported: 92.73% (votes for as printed: 82,734,939). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-21. Item 5.07 · say-on-pay result. As reported: 93.9% (votes for as printed: 84,194,484). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-08-25. Item 5.07 · say-on-pay result. As reported: 96.15% (votes for as printed: 72,610,991). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 778,211 + equity 2,062,643 + all other 0 = 2,840,854, summed across the director compensation table rows.
- PTC Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. View filing ↗
- Halozyme Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. View filing ↗
- Corcept Therapeutics Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Corcept Therapeutics Incorporated's own proxy. As printed: 15,303,551. View filing ↗
- Insmed Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Insmed Incorporated's own proxy. As printed: 14,467,393. View filing ↗
- Ionis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. View filing ↗
- Pacira BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. View filing ↗
- Ultragenyx Pharmaceutical, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Ultragenyx Pharmaceutical, Inc.'s own proxy. As printed: 11,405,535. View filing ↗
- Ani Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Ani Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. View filing ↗
- Amicus Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. View filing ↗
- Amphastar Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Amphastar Pharmaceuticals, Inc.'s own proxy. As printed: 8,309,350. View filing ↗
- Acadia Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. View filing ↗
- Dynavax Technologies Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Dynavax Technologies Corporation's own proxy. As printed: 8,210,775. View filing ↗
- Harmony Biosciences Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Harmony Biosciences Holdings, Inc.'s own proxy. As printed: 7,899,535. View filing ↗
- Catalyst Pharmaceuticals (subject), Section 10b CEO total. DEF 14A, filed 2025-04-11. CEO total compensation as printed in Catalyst Pharmaceuticals's own proxy. As printed: 7,774,160. View filing ↗
- Ironwood Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. View filing ↗
- Collegium Pharmaceutical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Collegium Pharmaceutical, Inc.'s own proxy. As printed: 1,715,846. View filing ↗
- Section 10a, Amicus Therapeutics, Inc. reciprocity. DEF 14A. Amicus Therapeutics, Inc. names Catalyst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Collegium Pharmaceutical, Inc. reciprocity. DEF 14A. Collegium Pharmaceutical, Inc. names Catalyst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Ani Pharmaceuticals, Inc. reciprocity. DEF 14A. Ani Pharmaceuticals, Inc. names Catalyst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Acadia Pharmaceuticals Inc. reciprocity. DEF 14A. Acadia Pharmaceuticals Inc. names Catalyst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). View filing ↗